Regeneron Pharmaceuticals Quarterly Income Statement
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Regeneron Pharmaceuticals generated $4.29 billion in revenue, up 16.7% from the same quarter a year earlier. Net income was $1.30 billion (-6.8% year over year), for a net margin of 30.2% versus a median of 26.7% in the prior 5 quarters. Operating margin was 30.1%.
Diluted earnings per share came in at $12.23, down from $12.81.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.29B | 3.61B | 3.88B | 3.75B | 3.68B | 3.03B | 3.79B | 3.72B | 3.55B | 3.15B | 3.43B | 3.36B |
| Revenue growth (YoY) | +16.73% | +19.04% | +2.51% | +0.90% | +3.62% | -3.70% | +10.33% | +10.65% | +12.32% | -0.54% | +0.58% | +14.53% |
| Research & Development | 1.63B | 1.54B | 1.63B | 1.48B | 1.42B | 1.33B | 1.41B | 1.27B | 1.20B | 1.25B | 1.18B | 1.08B |
| Selling, General & Admin | 662.10M | 647.70M | 775.00M | 657.80M | 634.20M | 633.00M | 792.20M | 714.40M | 758.80M | 689.00M | 737.70M | 640.50M |
| Operating Income | 1.29B | 642.90M | 879.90M | 1.03B | 1.08B | 591.70M | 990.20M | 1.18B | 1.07B | 751.40M | 972.90M | 1.11B |
| Interest Expense | 11.00M | 12.90M | 12.20M | 19.30M | 3.60M | 8.70M | 10.50M | 13.80M | 14.80M | 16.10M | 18.30M | 17.80M |
| Other Income (Expense) | 234.30M | 188.30M | 163.80M | 736.50M | 439.20M | 313.30M | -32.10M | 313.50M | 558.50M | -50.70M | 174.70M | -200.00K |
| Pretax Income | 1.53B | 831.20M | 1.04B | 1.76B | 1.52B | 905.00M | 958.10M | 1.49B | 1.63B | 700.70M | 1.15B | 1.11B |
| Income Tax | 230.90M | 104.00M | 199.10M | 303.30M | 127.10M | 96.30M | 40.40M | 152.40M | 195.80M | -21.30M | -12.00M | 103.00M |
| Net Income | 1.30B | 727.20M | 844.60M | 1.46B | 1.39B | 808.70M | 917.70M | 1.34B | 1.43B | 722.00M | 1.16B | 1.01B |
| Net Income growth (YoY) | -6.81% | -10.08% | -7.97% | +8.91% | -2.84% | +12.01% | -20.86% | +33.02% | +47.90% | -11.71% | -3.13% | -23.40% |
| EPS (Basic) | 12.62 | 6.99 | 8.16 | 14.09 | 13.24 | 7.58 | 8.55 | 12.40 | 13.25 | 6.70 | 10.88 | 9.48 |
| EPS (Diluted) | 12.23 | 6.75 | 7.78 | 13.62 | 12.81 | 7.27 | 8.12 | 11.54 | 12.41 | 6.27 | 10.21 | 8.89 |
| Shares Outstanding (Basic) | 102.80M | 104.00M | — | 103.60M | 105.10M | 106.70M | — | 108.10M | 108.10M | 107.80M | — | 106.30M |
| Shares Outstanding (Diluted) | 106.00M | 107.70M | — | 107.20M | 108.60M | 111.20M | — | 116.20M | 115.40M | 115.10M | — | 113.40M |
| EBITDA | 1.42B | 766.10M | 1.02B | 1.16B | 1.21B | 718.60M | 1.12B | 1.30B | 1.19B | 865.50M | 1.09B | 1.22B |
| Operating Margin | 30.15% | 17.83% | 22.65% | 27.35% | 29.37% | 19.54% | 26.13% | 31.70% | 30.15% | 23.89% | 28.33% | 33.04% |
| Net Margin | 30.23% | 20.17% | 21.74% | 38.89% | 37.86% | 26.70% | 24.22% | 36.03% | 40.38% | 22.96% | 33.77% | 29.97% |
This table shows 12 quarterly periods of Regeneron Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a income statement?